Fulcrum Therapeutics(FULC)2025-05-01 11:05Clinical Trials - Enrollment in the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD) is complete with 16 patients, and the 20 mg dose cohort has been initiated[2]. - Two abstracts accepted for presentation at the 2025 European Hematology Association Congress will highlight preclinical and clinical data related to pociredir[5]. - Pociredir has received FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD[10]. Financial Performance - Cash, cash equivalents, and marketable securities as of March 31, 2025, were $226.6 million, down from $241.0 million as of December 31, 2024, reflecting a decrease of $14.4 million[12]. - Research and development expenses for Q1 2025 were $13.4 million, a decrease of 32.4% compared to $19.8 million in Q1 2024[12]. - General and administrative expenses for Q1 2025 were $7.0 million, down 30.9% from $10.1 million in Q1 2024[12]. - Net loss for Q1 2025 was $17.7 million, compared to a net loss of $26.9 million in Q1 2024, representing a 34.2% improvement[12]. - The total stockholders' equity as of March 31, 2025, was $228.5 million, down from $243.0 million as of December 31, 2024[15]. Future Plans - The company expects its current cash position to fund operations into at least 2027[7]. - The company plans to submit an investigational new drug application (IND) for Diamond-Blackfan anemia during Q4 2025[5].